TESARO (TSRO) to Offer $300M in Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
TESARO (TSRO) Prices 4.65M Common Stock Offering at $81/Share
July 1, 2016 6:09 AM EDTTESARO, Inc. (Nasdaq: TSRO) announced that it has priced an underwritten public offering of an aggregate of 4,650,000 shares of its common stock at an offering price to the public of $81.00 per share. The gross proceeds from the offering will be approximately $376.7 million. In addition, TESARO has granted the underwriters an option to purchase up to an additional $56.5 million of... More
TESARO (TSRO) Niraparib Data Suggests PARP Inhibitors Will be Important - Stifel (CLVS) (AZN)
June 29, 2016 3:49 PM EDTClovis Oncology, Inc. (Nasdaq: CLVS) shares are trading strong Wednesday following phase 3 NOVA data from TESARO, Inc. (Nasdaq: TSRO), as announced... More
Tesaro (TSRO) Valuation Range Lifted to $122-$132 at Wells Fargo
June 29, 2016 9:48 AM EDTWells Fargo analyst Jim Birchenough raised his valuation range on Outperform-rated Tesaro (NASDAQ: TSRO) to $122-$132 from $88-495 following today's positive NOVA results.
For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.
Shares of Tesaro closed at $37.21 yesterday.
... MoreTESARO (TSRO) Nearly Doubles as Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
June 29, 2016 7:47 AM EDTTESARO (NASDAQ: TSRO) is surging 88% in pre-open trade after the company announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary... More
TESARO (TSRO) Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
June 29, 2016 7:02 AM EDTTESARO, Inc. (NASDAQ: TSRO) announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). This trial demonstrated that niraparib significantly prolonged PFS compared to control among patients who are germline BRCA mutation (gBRCAmut) carriers, among patients who are not germline BRCA mutation (non-gBRCAmut) carriers but who have homologous recombination deficient (HRD) tumors as determined by the Myriad myChoice® HRD test, and overall in patients who are not germline BRCA mutation carriers.
We are extremely grateful to the patients, caregivers, and investigators who participated in... More
